Outsourcing Pharma

  1. A Look At 2015 Outsourcing Trends And What To Expect In 2016

    This has been another exciting year in outsourcing, as mergers, acquisitions, and other collaborations continued with CROs and CMOs moving toward functioning as strategic partners.

  2. Building A Successful CMO/CRO Partnership: What’s Important To Emerging Pharma And Emerging Biotech?

    More than ever, pharmaceutical and biotechnology companies are considering CROs and CMOs as partners in collaboration to achieve long-term development goals.

  3. Innovation Moves Up In Rank And Technologies Move Into The Outsourcing Paradigm

    Now into the fifth year of examining outsourcing behaviors and ways contract suppliers can improve the drug development process, the results from the 2015 Nice Insight Biopharmaceutical Outsourcing Survey show that the biopharmaceutical industry is making some subtle changes in how it prioritizes companies when it comes to selecting a CRO or CMO.

  4. A Recap On 2014 Outsourcing Trends And What To Expect In 2015

    2014 was an exciting year in outsourcing. Several high profile mergers and acquisitions in both the CRO and CMO world will mean some familiar names will go through big changes — Huntingdon acquired Harlan, and PRA acquired RPS in the CRO world; Patheon acquired both DSM and Gallus Biopharma, and AMRI acquired Cedarburg and OsoBio in the CMO world.

  5. Real/Future Information Risk of R&D – CROs

    The jury is still out on the ultimate impact of healthcare reform in general, and perhaps this impact is even murkier in the life sciences  space.  Certainly there will be very dramatic changes to the providers (hospitals, primary care, etc.) and payers (insurance companies, health plans, etc.), but it is more difficult to see exactly how the changes will manifest themselves for the remaining entities in the health sciences arena.

  6. Maximizing Pipeline Value and Operational Efficiency through High Throughput Protein Expression

    At the core of every drug development program is the challenge to successfully express active, high quality product, and this is especially true of biologics. Indeed, very frequently drug developers are faced with protein expression issues, struggling to express a specific protein for months (and sometimes years) with varying degrees of success; low or no expression, insoluble expression, proteolytic clipping of the expressed protein or a combination thereof are examples of the hurdles encountered in product development efforts. Such challenges in protein expression are a major source of biopharmaceutical development delays, particularly as production strain development is typically performed in a linear and iterative fashion.

  7. API Manufacturing: Strategic Partnering Preferences With CMOs Vary Among Small-Molecule, High-Potency And Biologic API

    Data compiled from a strategic partner survey for outsourcing commercial-scale drug substance projects in API manufacturing revealed the differences in how buyers think about strategic partnerships with contract manufacturers.

  8. When Does A Supplier Become A Partner?

    Suppliers qualify for partner status when they share risk and responsibility, more than size and capabilities.

  9. A Successful Externalization Strategy Demands Modernized Informatics

    Outsourcing can enable cost cutting and taking advantage of specialized expertise. But the complexity can also open the door to errors, rework, product delays, and compliance issues. Here are three items that should be on your data management short list when outsourcing.

  10. Make Your CRO An Extension Of Your Internal Team

    The healthcare contract research outsourcing market is expected to grow from $25.1 billion in 2011 to $65 billion by 2018. Eight industry experts discuss how to turn your CRO into a strategic partner.